Two Democratic lawmakers are working to protect well being suppliers’ proper to prescribe managed substances through telehealth, together with stimulants for ADHD and buprenorphine for opioid dependancy.
A brand new invoice being drafted by Sen. Mark Warner (D-Va.) and Rep. Doris Matsui (D-Calif.) comes months earlier than the expiration of short-term waivers first enacted by the Drug Enforcement Administration’s through the Covid-19 pandemic. Although the DEA is at present considering new laws that might roll again most of the pandemic-era flexibilities, the lawmakers’ new invoice would probably prolong the present guidelines by way of 2026, in response to two lobbyists accustomed to the hassle.
The versatile guidelines are set to run out on the finish of the yr, which telehealth advocates say may threaten affected person entry to drugs, together with stimulants for ADHD and customary drugs used to deal with opioid dependancy.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
Have already got an account? Log in
View All Plans